Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha‐2b in metastatic melanoma (phase II DeCOG trial)

During a clinical study with combined therapy of sorafenib and pegylated interferon alpha‐2b (SoraPeg study) of the German Dermatologic Oncology Group (ADO/DeCOG), multiple and severe cutaneous side effects were observed. This study sought to analyze these cutaneous side effects, particularly because future studies with combinations of interferon alpha and targeted therapies are planned.

[1]  W. Rathmell,et al.  Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Caraglia,et al.  Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. , 2010, The oncologist.

[3]  A. Hauschild,et al.  Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low‐dose interferon alpha , 2007, International journal of cancer.

[4]  A. Hauschild,et al.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial , 2008, The Lancet.

[5]  E. Jonasch,et al.  Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. , 2009, Clinical genitourinary cancer.

[6]  J. Kirkwood,et al.  Prognostic significance of autoimmunity during treatment of melanoma with interferon , 2006, Seminars in Immunopathology.

[7]  S. Aamdal,et al.  Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. , 2009, Journal of the National Cancer Institute.

[8]  A. Hauschild,et al.  Does Basal Cell Carcinoma Belong to the Spectrum of Sorafenib-Induced Epithelial Skin Cancers? , 2010, Dermatology.

[9]  C. Robert,et al.  RAF inhibition and induction of cutaneous squamous cell carcinoma , 2011, Current opinion in oncology.

[10]  M. Weichenthal,et al.  Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  D. Schadendorf,et al.  Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. , 2012, European journal of cancer.

[12]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[13]  C. Robert,et al.  Dermatologic symptoms associated with the multikinase inhibitor sorafenib. , 2009, Journal of the American Academy of Dermatology.

[14]  A. Udvardi,et al.  Perforating folliculitis, angioedema, hand‐foot syndrome – multiple cutaneous side effects in a patient treated with sorafenib , 2009, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[15]  Dirk Strumberg,et al.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Robert,et al.  Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. , 2008, Archives of dermatology.

[17]  D. Schadendorf,et al.  Side effects of systemic oncological therapies in dermatology , 2012, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[18]  H. Kong,et al.  Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy , 2009, Clinical Cancer Research.

[19]  C. Tangen,et al.  Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  L. Heinzerling,et al.  Sarcoidosis Induced by Interferon-α in Melanoma Patients: Incidence, Clinical Manifestations, and Management Strategies , 2010, Journal of immunotherapy.

[21]  J. Guilhou,et al.  A Prospective Study of Cutaneous Adverse Events Induced by Low-Dose Alpha-Interferon Treatment for Malignant Melanoma , 2004, Dermatology.

[22]  D. Strumberg,et al.  Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? , 2006, European journal of cancer.

[23]  D. West,et al.  Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib , 2008, Supportive Care in Cancer.

[24]  J. Soria,et al.  Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Valérie Joncas,et al.  A distinct cutaneous reaction to sorafenib and a multikinase inhibitor , 2008, International journal of dermatology.

[26]  M. Alter,et al.  The hand‐foot‐syndrome associated with medical tumor therapy – classification and management , 2010, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[27]  R. Perez-soler,et al.  Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  W. Sterry,et al.  [Cutaneous side effects of clinically relevant cytokine therapies]. , 2003, Deutsche medizinische Wochenschrift.